June 30, 2014
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of cobas® 6500, a fully automated urine testing system that consists of two modular analyzers combining urine strip testing and digital urinary microscopy. The system tests for 23 parameters to help diagnose diseases such as urinary tract infection, kidney disease, and diabetes. The cobas® 6500 offers the highest throughput on the market, ensures high-quality results and increases laboratory productivity significantly, while reducing manual steps and contamination risks for laboratory staff.
The system will be available in in Europe, the Asia Pacific region, the Middle East, Africa and Latin America. Roche is also planning to submit an application for the approval of the cobas® 6500 in the United States.
About urine analysis (urinalysis)
Urinalysis has been an important diagnostic tool for more than hundred years. Urine remains a key indicator of many diseases such as urinary tract infection, kidney disease and diabetes. Urinalysis can reveal serious damage that is asymptomatic in early stages yet treatable when identified in time. The urine test strip is a key diagnostic tool that yields quick and reliable information on pathological changes in the urine. Its diagnostic significance lies primarily in first-line diagnosis, screening during routine or preventive examinations, and treatment monitoring.
About cobas® 6500 urine analyzer series
The cobas® 6500 consists of two modular analyzers: The urine test strip analysis module quickly tests for the risk of diseases such as kidney disease and urinary tract infection. The second module replaces the manual steps involved in urine microscopy and allows for fully automated quantification and classification of urine particles such as blood cells by digital microscopy. The unit significantly speeds up the microscopy process with as many as 116 test samples per hour, while eliminating variability of test results, driving standardization. For flexible use, the two modules can be operated separately or together as a single platform.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the WHO Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.